D1-06: Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer?  by Chen, Lei et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S391
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
D1-04 SCLC, Thu, 12:30 - 14:15
Cisplatin (Cis) + etoposide (VP16) vs. cis + irinotecan (CPT11) 
in extensive stage small cell lung cancer (E-SCLC): Updated 
pharmacogenomic (SWOG 0124) and comparative toxicity analysis 
(JCOG 9511 & SWOG 0124)
Lara, Primo N.1 Redman, Mary2 Natale, Ronald3 Lenz, Heinz 
Josef4 Gordon, Michael4 Shibata, Taro5 Fukuda, Haruhiko5 Tamura, 
Tomohide5 Saijo, Nagahiro5 Crowley, John2 Gandara, David R.6 
1 University of California Davis Cancer Center, Sacramento, CA, USA 
2 Southwest Oncology Group, Seattle, WA, USA 3 Cedars-Sinai, Los 
Angeles, CA, USA 4 University of Southern California, Los Angeles, CA, 
USA 5 Japan Clinical Oncology Group, Tokyo, Japan 6 University of 
California Davis, Sacramento, CA, USA 
Introduction: S0124 is a recently completed North American phase III 
trial designed to conﬁrm the results of J9511 which previously showed 
a signiﬁcant survival beneﬁt for Cis/CPT11 over Cis/VP16 in Japanese 
patients (pts). S0124 employed the same J9511 treatment protocol. One 
hypothesis is that toxicities would differ between North American & 
Japanese pts due partly to differences in the proportion of genetic poly-
morphisms involved in chemotherapy metabolism in these populations.
Methods: Patient level toxicity data were compared among 706 pts 
enrolled in J9511 & S0124 receiving common treatment using a logis-
tic model adjusted for age, sex, and performance status (PS). Select 
polymorphisms of the UGT1A1, ABCB1, OATP, & GSTP1 genes in 
genomic DNA were evaluated in 142 pts in S0124 (67 Cis/CPT11; 75 
Cis/VP16). Associations between toxicity & genotype within each arm 
were assessed using logistic regression.
Results: Pt demographics for J9511 & S0124, respectively: Mean age - 
61 & 62 years; Male sex - 131 (86%) & 315 (57%); PS 0 - 19 (13%) & 
173 (31%); PS>0 - 133 (87%) & 372 (68%). Comparative hematologic 
toxicities (> grade 3) are summarized below. 
Cis/CPT11 Cis/VP16
J9511 
(n=75)
S0124 
(n=278)
J9511 
(n=77)
S0124 
(n=276)
Neutropenia 49 (65%)* 88 (32%) 71 (92%)* 182 (66%)
Leukopenia 20 (27%)*** 48 (17%) 41 (53%)** 92 (33%)
Anemia 21 (28%)* 16 (6%) 25 (32%)** 36 (13%)
Platelets 4 (5%) 10 (4%) 14 (18%) 42 (15%)
*P<0.0001
**P<0.01
***P=0.02
There were no signiﬁcant differences in grade 3+ non-hematologic 
toxicities between studies. Polymorphism frequencies in S0124 pts: 
ABCB1*1236 (C/C 39%; T/C 61%; T/T 0%); *3435 (C/C 31%; C/T 
46%; T/T 24%); *2627 (G/G 57%; T/G 43%; T/T 0%); UGT1A1*28 
(6/6 38%; 6/7 59%; 7/7 4%); *3156 (A/A 10%; A/G 49%; G/G 41%); 
OATP-C*521 (m/m 2%, w/m 36%, w/w 61%). ABCBq*3435 T/T was 
associated with an increased risk of CPT11 grade 3+ diarrhea (p=0.04) 
vs. C/C and C/T. UGT1A1*3156 A/A was associated with increased 
risk of CPT11 neutropenia (p=0.009) & leukopenia (p=0.05). No gene 
tested was associated with VP16 toxicity.
Conclusions: Signiﬁcant differences in treatment-related myelosup-
pression exist between J9511 and S0124 pt populations. Certain poly-
morphisms in genes involved in CPT11 metabolism are signiﬁcantly 
associated with CPT11 toxicities in S0124 pts. These results support 
the hypothesis that toxicities may be associated with distribution of 
genetic polymorphisms. Updated outcomes data from S0124 will be 
presented.
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Background: Bevacizumab’s role in the treatment of small-cell lung 
cancer is unknown. A multicenter phase II trial with bevacizumab and 
chemotherapy was conducted in patients with untreated extensive-stage 
small-cell lung cancer. 
Methods: The primary objective of this trial was to improve the histori-
cal median time to progression (TTP) of 6 months by 40%. Eligibility 
criteria included: no prior chemotherapy for small-cell lung cancer, no 
active brain metastases, normal organ function, no hemoptysis, ECOG 
PS 0-1, measurable disease, and signed informed consent. Treatment 
consisted of: irinotecan 60mg/m2 IV days 1, 8, 15, carboplatin AUC=4 IV 
day 1, and bevacizumab 10 mg/kg IV days 1 and 15 every 28 days. Re-
staging studies were performed every 2 cycles (8 weeks). If there was no 
evidence of progressive disease after 4-6 cycles of combination therapy, 
patients went on to receive maintenance bevacizumab for 6 months. 
Results: 44 pts have been enrolled from 2/06 to 3/07 (n=50 planned), 
with a median follow-up of 9 months. Baseline features included: 
median age 66 years (range 46-81); male/female, 57%/43%; 3 patients 
(7%) with previously treated brain metastases; 89% current or former 
smokers; and ECOG PS 0/1, 32%/68%. The objective response rate 
was 72% (95% CI 55%-85%), including 2 complete responses and 21 
partial responses. 7 patients (22%) had stable disease and 2 patients had 
progressive disease at restaging. 12 patients were not evaluable due to: 
comorbidity (off study), 2 patients; being too early for restaging, 10 
patients. TTP and overall survival data are not mature at the time of this 
analysis. Grade 3/4 toxicity has been limited: diarrhea (26%), fatigue 
(13%), and neutropenia (13%). There has been no signiﬁcant bleeding 
to date. 
Conclusions: Bevacizumab can be safely added to carboplatin and 
irinotecan in the ﬁrst-line treatment of extensive-stage small-cell 
lung cancer. Analysis of TTP will soon be mature to better estimate 
bevacizumab’s role in this setting. Ultimately, randomized trials will 
best assess bevacizumab’s efﬁcacy in small-cell lung cancer treatment.
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Background: Lung cancer symptoms may be very burdensome for pa-
tients with small cell lung cancer (SCLC) and may result in impairment 
in quality of life and health status. The objective of the present study 
is to compare the health status of patients treated with oral topotecan 
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plus best supportive care (OT+ BSC) versus best supportive care (BSC) 
alone using the EQ-5D assessment in a clinical trial in SCLC. Informa-
tion from ongoing studies supports that a minimal important difference 
(MID) in lung cancer of 0.08 can be used to further interpret results 
obtained for EQ-5D Index.
Methods: Data were analyzed from a randomized, open-label, mul-
ticenter trial in 141 SCLC patients receiving either OT+BSC or BSC 
alone where health status was assessed by patient self-report using the 
EQ-5D Index and the EQ-5D Visual Analogue Scale (VAS). EQ-5D is 
a questionnaire that covers multi-attribute health outcomes, including 
mobility, self-care, usual activity, pain/discomfort, and anxiety/depres-
sion, as an overall measurement of patient health status. The Index 
is scored on a scale from 0 (dead) to 1 (perfect health), and the VAS 
scores range from 0 (worst health) to 100 (best health). The EQ-5D 
measures were administered at baseline and at 3-week intervals at 
subsequent four visits. Change from baseline in EQ-5D Index and EQ-
5D-VAS was assessed using a pooled analysis (change from baseline to 
averaged on-treatment assessments) and also considering only change 
from baseline to last evaluation. Rate of change in EQ-5D Index scores 
(rate at which symptoms improved or deteriorated) across treatment 
groups was analyzed using a mixed model to account for repeated 
measurements over the treatment course. 
Results: A signiﬁcantly smaller decline in EQ-5D Index and VAS 
change scores were observed for the OT+BSC than BSC groups in both 
pooled and last evaluation analyses (Table). The rate of change from 
baseline per 3-month interval for EQ-5D Index score was -0.05 (95% 
CI: -0.11, 0.02) for OT+BSC and -.20 (95% CI, -0.27, -0.12) for BSC, 
indicating a decline for both groups, but a signiﬁcantly slower decline 
for OT+BSC.
Table: Change in EQ-5D Scores from Baseline to Treatment Periods
 Baseline Treatment Change from baseline   
 Mean Mean Mean Diﬀerence  (OT+BSC vs. BSC) p value
Pooled Analysis 
EQ-5D Index 
OT+BSC (n=239) 0.72 0.69 -0.03   
BSC (n=167) 0.68 0.56 -0.12 0.09 0.0036
EQ-5D VAS 
OT+BSC (n=238) 66.46 66.76 0.30   
BSC (n=162) 67.22 59.80 -7.41 7.71 <0.0001
Change from Baseline to Last Evaluation Analysis 
EQ-5D Index 
OT+BSC (n=61) 0.70 0.61 -0.10   
BSC (n=51) 0.65 0.34 -0.30 0.2 0.0034
EQ-5D VAS 
OT+BSC (n=60) 65.75 61.77 -3.98   
BSC (n=48) 64.29 49.83 -14.46 10.48 0.0025
 
Conclusion: Results for the EQ-5D Index indicate a smaller and slower 
decline in health status from baseline for OT+BSC compared to BSC. 
The between groups difference in magnitude of decline exceeded the 
established MID. In addition, results for EQ-5D VAS also showed a 
smaller decline for OT+BSC.
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Background: Small cell lung cancer (SCLC) makes up 15-20% of 
all lung cancer cases worldwide. SCLC is a very aggressive form of 
cancer and is characterised by early metastasis. As a result, chemo-
therapy is the mainstay of treatment in SCLC. A number of different 
platinum based and non-platinum based chemotherapy regimes have 
been trialled for the treatment of SCLC, with varying results. The aim 
of this project was to analyse the data from these trials in a Cochrane 
systematic review (SR) comparing platinum vs. non-platinum base che-
motherapy regimes in SCLC with regards to survival, tumour response, 
toxicity and quality of life (QOL).
Methods: A search of biomedical literature databases (MEDLINE, 
EMBASE, CINAHL, CENTRAL) was conducted in order to identify 
all randomised controlled trials that involved patients with histologi-
cally conﬁrmed SCLC and the use of platinum based chemotherapy 
regimes. Information about included trials was recorded in order to 
assess for methodological quality. The following results from the 
included trials were also recorded: Survival (at 6 months, 12 months 
and 24 months), tumour response (objective overall response (OOR)), 
complete response (CR)), toxicity and QOL. The results of the survival, 
tumour response and toxicity data were combined in a meta-analysis.
Results: A total of 29 trials involving 5530 patients were included in 
this SR. In terms of 6 month survival, there was a statistically signiﬁ-
cant difference favouring platinum based chemotherapy regimes (Odds 
ratio (OR) 1.19; 95% CI: 1.06-1.35). Platinum based chemotherapy 
regimes were also favoured in terms of 12 month and 24 month sur-
vival, however, for these time periods, the difference was not statisti-
cally signiﬁcant. OR for twelve month survival was 1.08 (0.97-1.22) 
and 24 month survival was 1.05 (0.87-1.26). There was a statistically 
signiﬁcant difference favouring platinum based chemotherapy regimes 
in terms of OOR and CR. The OR for OOR was 1.26 (1.12-1.41) and 
for CR was 1.39 (1.21-1.59). Platinum based chemotherapy regimes 
had signiﬁcantly higher rates of nausea and vomiting (OR 1.58; 1.28-
1.94), anaemia (OR 1.72; 1.26-2.35) and thrombocytopaenia (OR 3.44; 
2.68-4.41) toxicity. Non-platinum based chemotherapy regimes had a 
signiﬁcantly higher rate of leukopaenia toxicity (OR 0.75; 0.62-0.91). 
There was no signiﬁcant difference in the rate of toxic death (OR 1.09; 
0.77-1.54). Only 3 trials presented QOL data and the data presented by 
these trials was not able to be combined in a meta-analysis.
Conclusion: Despite platinum based chemotherapy regimes invoking 
a signiﬁcantly higher tumour response, both in terms of OOR and CR, 
these regimes did not offer a signiﬁcant long-term survival beneﬁt over 
non-platinum based chemotherapy regimes. Platinum based chemo-
therapy regimes were associated with higher rates of toxicity, except 
for leukopaenia toxicity. This SR also highlighted the lack of QOL data 
in trials involving chemotherapy treatment for SCLC. With poor long-
term survival associated with both treatment groups, the issue of the 
QOL of the survival period takes on even more signiﬁcance. It would 
be beneﬁcial for future trials into this area to include a QOL assess-
ment.
